H. Manning
Faculty Member
Last active: 3/22/2018

Preclinical TSPO Ligand PET to Visualize Human Glioma Xenotransplants: A Preliminary Study.

Buck JR, McKinley ET, Fu A, Abel TW, Thompson RC, Chambless L, Watchmaker JM, Harty JP, Cooper MK, Manning HC
PLoS One. 2015 10 (10): e0141659

PMID: 26517124 · PMCID: PMC4627825 · DOI:10.1371/journal.pone.0141659

Current positron emission tomography (PET) imaging biomarkers for detection of infiltrating gliomas are limited. Translocator protein (TSPO) is a novel and promising biomarker for glioma PET imaging. To validate TSPO as a potential target for molecular imaging of glioma, TSPO expression was assayed in a tumor microarray containing 37 high-grade (III, IV) gliomas. TSPO staining was detected in all tumor specimens. Subsequently, PET imaging was performed with an aryloxyanilide-based TSPO ligand, [18F]PBR06, in primary orthotopic xenograft models of WHO grade III and IV gliomas. Selective uptake of [18F]PBR06 in engrafted tumor was measured. Furthermore, PET imaging with [18F]PBR06 demonstrated infiltrative glioma growth that was undetectable by traditional magnetic resonance imaging (MRI). Preliminary PET with [18F]PBR06 demonstrated a preferential tumor-to-normal background ratio in comparison to 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG). These results suggest that TSPO PET imaging with such high-affinity radiotracers may represent a novel strategy to characterize distinct molecular features of glioma growth, as well as better define the extent of glioma infiltration for therapeutic purposes.

MeSH Terms (16)

Acetanilides Animals Brain Neoplasms Cell Line, Tumor Gene Expression Regulation, Neoplastic Glioma Humans Male Mice Neoplasm Transplantation Positron-Emission Tomography Radiopharmaceuticals Rats Receptors, GABA Sensitivity and Specificity Tissue Array Analysis

Connections (1)

This publication is referenced by other Labnodes entities:

Links